论文部分内容阅读
目的观察细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)治疗恶性肿瘤中出现的不良反应、不良反应出现的可能原因及针对性治疗措施。方法回顾分析2008年3月-2012年10月730例恶性肿瘤患者回输CIK细胞悬液后各种不良反应的临床表现、实验室检查结果、采取的治疗措施及分析可能的原因。结果 CIK细胞回输后的不良反应有:发热(6.85%)、皮疹(1.64%)、消化道不适(0.96%)、关节疼痛(0.41%)、类过敏样反应及溶瘤综合征(均为0.14%)、类全身炎症反应综合征样反应(0.68%),除合并血压下降、严重过敏样反应及溶瘤综合征需对症处理外,余无需特殊处理。不良反应原因可能与CIK细胞的归巢特征及个体差异有关。结论此疗法是安全有效的过继免疫治疗方法,相关不良反应经积极对症处理后可恢复。
Objective To observe the adverse reactions of cytokine-induced killer (CIK) in the treatment of malignant tumors, the possible causes of adverse reactions and the targeted treatment. Methods The clinical manifestations, laboratory tests, treatment measures and possible causes of various adverse reactions of 730 patients with malignant tumor after CIK cell suspension transfusion were retrospectively analyzed from March 2008 to October 2012. Results Adverse reactions after CIK cells were transfused were fever (6.85%), rash (1.64%), digestive tract discomfort (0.96%), joint pain (0.41%), anaphylactoid reaction and oncolytic syndrome 0.14%). The systemic inflammatory response syndrome-like reaction (0.68%) required no symptomatic treatment except for the combination of decreased blood pressure, severe allergic reaction and oncolytic syndrome. Adverse reactions may be due to homing characteristics and individual differences in CIK cells. Conclusion This therapy is a safe and effective adoptive immunotherapy, and the related adverse reactions can be recovered after active symptomatic treatment.